Double-blind, placebo-controlled study of terfenadine and hydroxyzine in patients with chronic idiopathic urticaria.
Results of a double-blind, randomized, placebo-controlled, parallel study in 37 patients indicate that terfenadine, 60 mg bid, is significantly more effective than placebo and as effective as hydroxyzine, 25 mg qid, in the treatment of chronic idiopathic urticaria without causing the somnolence that was associated with the use of hydroxyzine.
Boggs
P B
PB
Asthma-Allergy Clinic, Shreveport, LA.
Ellis
C N
CN
Grossman
J
J
Washburne
W F
WF
Gupta
A K
AK
Ball
R
R
Shulan
D
D
D000293:Adolescent; D000328:Adult; D001559:Benzhydryl Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D002908:Chronic Disease; D004311:Double-Blind Method; D006634:Histamine H1 Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D006919:Hydroxyzine / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic; D016593:Terfenadine; D014581:Urticaria / Q000188:drug therapy*
D001559:Benzhydryl Compounds; D006634:Histamine H1 Antagonists; D006919:Hydroxyzine; D016593:Terfenadine